| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Tranylcypromine HCl (also known as SKF385 HCl; 2-PCPA) is discontinued. It is the hydrochloride salt of Tranylcypromine which is a nonselective and irreversible monoamine oxidase/MAO inhibitor used as an antidepressant drug. It inhibits CYP2A6 with Kis of 0.08 μM and 0.2 μM in cDNA-expressing microsomes and Human Liver Microsomes, respectively. Tranylcypromine is used as an antidepressant and anxiolytic agent in the clinical treatment of mood and anxiety disorders, respectively.
| ln Vitro |
Human primary keratinocytes transduced by two factors, Oct4 and Klf4, undergo reprogramming when Tranylcypromine (SKF 385) (GMP) and Laduviglusib are combined [2].
|
|---|---|
| ln Vivo |
In wild-type mice, tranylcypromine hydrochlorid (3 mg/kg; intraperitoneal; once daily for three days) reduces proinflammatory cytokine COX-2 and IL-6 levels as well as LPS-mediated microglial activation[3]. In 5xFAD mice, tranylcypromine hydrochlorid (3 mg/kg; intraperitoneal; once daily for 7 days) reduces Aβ-mediated microglial activation[3].
|
| Animal Protocol |
Animal/Disease Models: Wild-type mice[3]
Doses: 3 mg/kg Route of Administration: intraperitoneal (ip)injection; 3 mg/kg one time/day for 3 days Experimental Results: Dramatically down-regulated LPS-stimulated microglial activation in the cortex and Hippocampus, and LPS-induced astrocyte activation only in the cortex. decreased LPS-induced COX-2 levels in hippocampus CA1, diminished LPS-evoked IL-6 levels in the cortex and hippocampus CA1 and suppressed LPS-mediated IL-1β levels in the cortex. Animal/Disease Models: 5xFAD mice[3] Doses: 3 mg/kg Route of Administration: intraperitoneal (ip)injection; 3 mg/kg one time/day for 7 days Experimental Results: Differentially regulated microglial and astrocyte activation in this mouse model of AD. |
| References |
Drug Metab Dispos.2001 Jun;29(6):897-902;Environ Health Perspect.2004 Aug;112(11):1159-64.
|
| Additional Infomation |
(1R,2S)-tranylcypromine hydrochloride is a hydrochloride obtained by combining (1R,2S)-tranylcypromine with one equivalent of hydrochloric acid. It contains a (1R,2S)-tranylcypromine(1+). It is an enantiomer of a (1S,2R)-tranylcypromine hydrochloride.
See also: Tranylcypromine (annotation moved to). |
| Molecular Formula |
C9H12CLN
|
|
|---|---|---|
| Molecular Weight |
169.65
|
|
| Exact Mass |
169.065
|
|
| CAS # |
1986-47-6
|
|
| Related CAS # |
|
|
| PubChem CID |
2723716
|
|
| Appearance |
White to yellow solid powder
|
|
| Boiling Point |
218.3ºC at 760mmHg
|
|
| Melting Point |
162-169ºC(lit.)
|
|
| Flash Point |
90.8ºC
|
|
| Vapour Pressure |
0.127mmHg at 25°C
|
|
| LogP |
3.003
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
1
|
|
| Rotatable Bond Count |
1
|
|
| Heavy Atom Count |
11
|
|
| Complexity |
116
|
|
| Defined Atom Stereocenter Count |
2
|
|
| SMILES |
C1[C@H]([C@@H]1N)C2=CC=CC=C2.Cl
|
|
| InChi Key |
ZPEFMSTTZXJOTM-OULXEKPRSA-N
|
|
| InChi Code |
InChI=1S/C9H11N.ClH/c10-9-6-8(9)7-4-2-1-3-5-7;/h1-5,8-9H,6,10H2;1H/t8-,9+;/m0./s1
|
|
| Chemical Name |
trans-2-Phenylcyclopropylamine Hydrochloride
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.74 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.74 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (14.74 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8945 mL | 29.4724 mL | 58.9449 mL | |
| 5 mM | 1.1789 mL | 5.8945 mL | 11.7890 mL | |
| 10 mM | 0.5894 mL | 2.9472 mL | 5.8945 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT01430455 | Completed Has Results | Drug: Tranylcypromine | Bipolar Disorder I or II | New York State Psychiatric Institute | November 2011 | Phase 4 |
| NCT00653393 | Completed | Drug: Tranylcypromine Drug: Parnate |
To Determine the Bioavailability of Tranylcypromine |
Par Pharmaceutical, Inc. | October 2004 | Phase 1 |
| NCT00296686 | Terminated | Drug: Tranylcypromine Drug: Dextroamphetamine |
Major Depression | New York State Psychiatric Institute | September 2001 | Phase 4 |
| NCT02273102 | Completed | Drug: Tranylcypromine Drug: Tretinoin |
Acute Myelogenous Leukemia Myelodysplastic Syndromes |
University of Miami | March 2, 2015 | Phase 1 |
|
|---|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
